

# UNDERSTANDING *BRAF* MUTATIONS IN METASTATIC COLORECTAL CANCER

Patients with metastatic CRC harboring mutations in the *BRAF* gene suffer a worse prognosis than patients with wild-type *BRAF*. You're invited to join ([click here](#)) **John L. Marshall, MD** as he discusses the role of *BRAF* mutations in mCRC and the importance to test all metastatic patients for this mutation at diagnosis.

**Monday, June 17, 2019**  
**9:30 AM to 10:30 AM (EDT)**



**John L. Marshall, MD,**  
Chief, Division of Hematology/ Oncology,  
Medstar Georgetown University Hospital,  
Director, Otto J. Ruesch Center for the  
Cure of Gastrointestinal Cancer

Featured topics will include:

- *BRAF*-Mutations in Metastatic Colorectal Cancer
- The MAPK Signaling Pathway in Colorectal Cancer
- National Comprehensive Cancer Network® (NCCN®) mCRC Testing Recommendations



Register for the webinar here: [Click here](#)